The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in pharma: CKD treatment compositionsBuy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilizing and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

80+ innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 668,000 patents, there are 80+ innovation areas that will shape the future of the industry.

Within the emerging innovation stage, engineered multispecific antibodies, tyrosine kinase inhibitors, and mutant DNA polymerases are disruptive technologies that are in the early stages of application and should be tracked closely. Phenotypic drug screening, antibody-drug conjugates, and polysaccharide-protein conjugate vaccines are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are drug delivery nanoparticles and antibody encoding polynucleotide libraries, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

CKD treatment compositions is a key innovation area in pharmaceutical

Chronic kidney disease (CKD) or chronic renal disease is a condition characterised by a gradual loss of kidney function over time. Diabetes and high blood pressure are the most common causes of kidney disease. Treatments include high blood pressure medications such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers to preserve kidney function, medications to relieve swelling etc.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 70+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of kidney disorder treatment compositions.

Key players in CKD treatment compositions – a disruptive innovation in the pharmaceutical industry industry  

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to CKD treatment compositions

Company Total patents (2021 - 2023) Premium intelligence on the world's largest companies
Boston Medical Center 50 Unlock Company Profile
Compagnie Merieux Alliance 45 Unlock Company Profile
AstraZeneca 39 Unlock Company Profile
Massachusetts General Hospital 39 Unlock Company Profile
Idexx Laboratories 36 Unlock Company Profile
Sanofi 36 Unlock Company Profile
Biogen 34 Unlock Company Profile
Kirin 33 Unlock Company Profile
MyCartis 25 Unlock Company Profile
Proteomics International Laboratories 24 Unlock Company Profile
Colgate-Palmolive 19 Unlock Company Profile
AbbVie 19 Unlock Company Profile
CareGroup 17 Unlock Company Profile
St Vincent’s Health Australia 14 Unlock Company Profile
Renibus Therapeutics 14 Unlock Company Profile
Immundiagnostik 13 Unlock Company Profile
OPKO Health 13 Unlock Company Profile
General Hospital 13 Unlock Company Profile
PerkinElmer 12 Unlock Company Profile
Pieris Pharmaceuticals 12 Unlock Company Profile
Mars 12 Unlock Company Profile
Mount Sinai Health System 11 Unlock Company Profile
Leadgene Biomedical 11 Unlock Company Profile
4TEEN4 Pharmaceuticals 10 Unlock Company Profile
Yaqrit 10 Unlock Company Profile
Tricida 9 Unlock Company Profile
Eli Lilly 9 Unlock Company Profile
Pieris 9 Unlock Company Profile
SP Nutraceuticals 9 Unlock Company Profile
F. Hoffmann-La Roche 8 Unlock Company Profile
Fred Hutchinson Cancer Research Center 8 Unlock Company Profile
Genera Istrazivanja d.o.o. 8 Unlock Company Profile
Maruha Nichiro 8 Unlock Company Profile
UAB Research Foundation 7 Unlock Company Profile
Bristol-Myers Squibb 7 Unlock Company Profile
Sysmex 7 Unlock Company Profile
Goldfinch Bio 7 Unlock Company Profile
L&F Research 6 Unlock Company Profile
Proventiv Therapeutics 5 Unlock Company Profile
Figene 5 Unlock Company Profile
Bouygues / VAMED Engineering / Assistance Publique - Hôpitaux de Paris JV 5 Unlock Company Profile
Takeda Pharmaceutical 5 Unlock Company Profile
Mayo Clinic 5 Unlock Company Profile
Centre National de la Recherche Scientifique 5 Unlock Company Profile
Akron Children's Hospital 4 Unlock Company Profile
Regeneron Pharmaceuticals 4 Unlock Company Profile
Rhythm Pharmaceuticals 4 Unlock Company Profile
Kantum Pharma 3 Unlock Company Profile
Assistance Publique - Hopitaux de Paris 3 Unlock Company Profile
The Cleveland Clinic Foundation 3 Unlock Company Profile

Source: GlobalData Patent Analytics

Boston Medical Center (BMC) is the leading patent filers in kidney disorder treatment compositions. The Renal Department at BMC is a nationally recognized research and training program in nephrology for more than five decades. The research focuses on the immunopathogenesis of glomerular diseases, structural biology of the glomerulus, mechanisms of autoimmunity, renal cystic disease and cancer, kidney development and mechanisms of cell injury in acute renal failure.

In terms of application diversity, Boston Medical Center is the top company, followed by F. Hoffmann-La Roche and Regeneron Pharmaceuticals. By means of geographic reach, AstraZeneca holds the top position, while Idexx Laboratories and Biogen are in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.